RVMD logo

Revolution Medicines, Inc. Common Stock

RVMD

RVMD: Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

more

Show RVMD Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of RVMD by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by RVMD's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric shp2 inhibitors Aug. 29, 2023
  • Patent Title: Ras inhibitors Aug. 29, 2023
  • Patent Title: Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors Jul. 18, 2023
  • Patent Title: Ras inhibitors Jul. 04, 2023
  • Patent Title: C26-linked rapamycin analogs as mtor inhibitors Jun. 27, 2023
  • Patent Title: Polycyclic compounds as allosteric shp2 inhibitors Jun. 13, 2023
  • Patent Title: Pyridine compounds as allosteric shp2 inhibitors Jun. 13, 2023
  • Patent Title: 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors May. 30, 2023
  • Patent Title: Identifying new therapeutic agents May. 09, 2023
  • Patent Title: Polycyclic compounds as allosteric shp2 inhibitors Apr. 25, 2023
  • Patent Title: Ras inhibitors Mar. 21, 2023
  • Patent Title: Shp2 inhibitor compositions and methods for treating cancer Mar. 07, 2023
  • Patent Title: Ras inhibitors Jan. 31, 2023
  • Patent Title: C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors Jun. 21, 2022
  • Patent Title: Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a shp2 inhibitor Jan. 11, 2022
  • Patent Title: Bicyclic heteroaryl compounds and uses thereof Nov. 09, 2021
  • Patent Title: Compounds that participate in cooperative binding and uses thereof Jul. 13, 2021
  • Patent Title: Identifying new therapeutic agents Apr. 27, 2021
  • Patent Title: C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors Apr. 20, 2021
  • Patent Title: Methods and reagents for analyzing protein-protein interfaces Mar. 16, 2021
  • Patent Title: 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors Mar. 17, 2020
  • Patent Title: Compounds that participate in cooperative binding and uses thereof Jan. 14, 2020
  • Patent Title: Methods and reagents for analyzing protein-protein interfaces Nov. 05, 2019
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of RVMD in WallStreetBets Daily Discussion

RVMD News

Recent insights relating to RVMD

CNBC Recommendations

Recent picks made for RVMD stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RVMD

Corporate Flights

Flights by private jets registered to RVMD